Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)

Detalles Bibliográficos
Autores principales: Dhainaut, J, Antonelli, M, Wright, P, Belger, M, Cobas-Meyer, M, Mignini, M, Janes, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088576/
http://dx.doi.org/10.1186/cc6426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088576/
http://dx.doi.org/10.1186/cc6426

Ejemplares similares